BindingDB logo
myBDB logout

Patent code US10118930

Compile Data Set for Download or QSAR

Found 465 hits of Enzyme Inhibition Constant Data   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298092
PNG
(3-[3-(2-tert-butoxyethyl)-1,2,4-oxadiazol-5-yl]-2-...)
Show SMILES Cc1nn2c(cc(=O)[nH]c2c1-c1nc(CCOC(C)(C)C)no1)C1CCNCC1
Show InChI InChI=1S/C20H28N6O3/c1-12-17(19-22-15(25-29-19)7-10-28-20(2,3)4)18-23-16(27)11-14(26(18)24-12)13-5-8-21-9-6-13/h11,13,21H,5-10H2,1-4H3,(H,23,27)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 6n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298255
PNG
(3-(cyclopropylcarbonyl)-7-(piperidin-4-yl)pyrazolo...)
Show SMILES O=C(C1CC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C15H18N4O2/c20-13-7-12(9-3-5-16-6-4-9)19-15(18-13)11(8-17-19)14(21)10-1-2-10/h7-10,16H,1-6H2,(H,18,20)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 8n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298254
PNG
(3-(2-methylbutanoyl)-7-(piperidin-4-yl)pyrazolo[1,...)
Show SMILES CCC(C)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C16H22N4O2/c1-3-10(2)15(22)12-9-18-20-13(8-14(21)19-16(12)20)11-4-6-17-7-5-11/h8-11,17H,3-7H2,1-2H3,(H,19,21)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 8n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298041
PNG
(3-(2-methyl-1,3-thiazol-5-yl)-7-(piperidin-4-yl)py...)
Show SMILES Cc1ncc(s1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C15H17N5OS/c1-9-17-8-13(22-9)11-7-18-20-12(6-14(21)19-15(11)20)10-2-4-16-5-3-10/h6-8,10,16H,2-5H2,1H3,(H,19,21)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 8.20n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297950
PNG
(7-(piperidin-4-yl)-3-{5-[4-(trifluoromethyl)phenyl...)
Show SMILES FC(F)(F)c1ccc(cc1)-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C20H17F3N6O2/c21-20(22,23)13-3-1-12(2-4-13)18-27-28-19(31-18)14-10-25-29-15(9-16(30)26-17(14)29)11-5-7-24-8-6-11/h1-4,9-11,24H,5-8H2,(H,26,30)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 8.70n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298123
PNG
(3-(4-cyclohexyl-1,3-thiazol-2-yl)-7-(piperidin-4-y...)
Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3nc(cs3)C3CCCCC3)c2[nH]1
Show InChI InChI=1S/C20H25N5OS/c26-18-10-17(14-6-8-21-9-7-14)25-19(24-18)15(11-22-25)20-23-16(12-27-20)13-4-2-1-3-5-13/h10-14,21H,1-9H2,(H,24,26)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 9n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298115
PNG
(7-(piperidin-4-yl)-3-(piperidin-1-ylcarbonyl)pyraz...)
Show SMILES O=C(N1CCCCC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C17H23N5O2/c23-15-10-14(12-4-6-18-7-5-12)22-16(20-15)13(11-19-22)17(24)21-8-2-1-3-9-21/h10-12,18H,1-9H2,(H,20,23)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 9n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298009
PNG
(3-[3-(4-fluorobenzyl)-1,2,4-oxadiazol-5-yl]-7-(pip...)
Show SMILES Fc1ccc(Cc2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1
Show InChI InChI=1S/C20H19FN6O2/c21-14-3-1-12(2-4-14)9-17-24-20(29-26-17)15-11-23-27-16(10-18(28)25-19(15)27)13-5-7-22-8-6-13/h1-4,10-11,13,22H,5-9H2,(H,25,28)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 9.70n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298237
PNG
(3-[3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-2-met...)
Show SMILES COc1ccccc1-c1noc(n1)-c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C21H22N6O3/c1-12-18(21-24-19(26-30-21)14-5-3-4-6-16(14)29-2)20-23-17(28)11-15(27(20)25-12)13-7-9-22-10-8-13/h3-6,11,13,22H,7-10H2,1-2H3,(H,23,28)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 10n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298246
PNG
(3-[3-(4-hydroxybenzyl)-1,2,4-oxadiazol-5-yl]-2-met...)
Show SMILES Cc1nn2c(cc(=O)[nH]c2c1-c1nc(Cc2ccc(O)cc2)no1)C1CCNCC1
Show InChI InChI=1S/C21H22N6O3/c1-12-19(21-23-17(26-30-21)10-13-2-4-15(28)5-3-13)20-24-18(29)11-16(27(20)25-12)14-6-8-22-9-7-14/h2-5,11,14,22,28H,6-10H2,1H3,(H,24,29)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 10n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298073
PNG
(3-[5-(2-phenylethyl)-1,3,4-oxadiazol-2-yl]-7-(pipe...)
Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3nnc(CCc4ccccc4)o3)c2[nH]1
Show InChI InChI=1S/C21H22N6O2/c28-18-12-17(15-8-10-22-11-9-15)27-20(24-18)16(13-23-27)21-26-25-19(29-21)7-6-14-4-2-1-3-5-14/h1-5,12-13,15,22H,6-11H2,(H,24,28)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 10n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298184
PNG
(Rel-3-{5-[(1R,2S)-2-methylcyclopentyl]-1,2,4-oxadi...)
Show SMILES CC1CCCC1c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C19H24N6O2/c1-11-3-2-4-13(11)19-23-17(24-27-19)14-10-21-25-15(9-16(26)22-18(14)25)12-5-7-20-8-6-12/h9-13,20H,2-8H2,1H3,(H,22,26)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 10n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298127
PNG
(3-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-2-methyl-7-(...)
Show SMILES Cc1nn2c(cc(=O)[nH]c2c1-c1nnc(o1)C(C)(C)C)C1CCNCC1
Show InChI InChI=1S/C18H24N6O2/c1-10-14(16-21-22-17(26-16)18(2,3)4)15-20-13(25)9-12(24(15)23-10)11-5-7-19-8-6-11/h9,11,19H,5-8H2,1-4H3,(H,20,25)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 11n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298170
PNG
(7-(piperidin-4-yl)-3-(1,2-thiazol-5-yl)pyrazolo[1,...)
Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3ccns3)c2[nH]1
Show InChI InChI=1S/C14H15N5OS/c20-13-7-11(9-1-4-15-5-2-9)19-14(18-13)10(8-16-19)12-3-6-17-21-12/h3,6-9,15H,1-2,4-5H2,(H,18,20)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 11n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298253
PNG
(3-(cyclopentylcarbonyl)-7-(piperidin-4-yl)pyrazolo...)
Show SMILES O=C(C1CCCC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C17H22N4O2/c22-15-9-14(11-5-7-18-8-6-11)21-17(20-15)13(10-19-21)16(23)12-3-1-2-4-12/h9-12,18H,1-8H2,(H,20,22)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 11n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297845
PNG
(5-[5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,...)
Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3cc(cs3)C#N)c2[nH]1
Show InChI InChI=1S/C16H15N5OS/c17-7-10-5-14(23-9-10)12-8-19-21-13(6-15(22)20-16(12)21)11-1-3-18-4-2-11/h5-6,8-9,11,18H,1-4H2,(H,20,22)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 11n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298063
PNG
(3-[5-(3-chlorobenzyl)-1,3,4-oxadiazol-2-yl]-7-(pip...)
Show SMILES Clc1cccc(Cc2nnc(o2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c1
Show InChI InChI=1S/C20H19ClN6O2/c21-14-3-1-2-12(8-14)9-18-25-26-20(29-18)15-11-23-27-16(10-17(28)24-19(15)27)13-4-6-22-7-5-13/h1-3,8,10-11,13,22H,4-7,9H2,(H,24,28)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 11n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298096
PNG
(2-methyl-3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-y...)
Show SMILES Cc1nn2c(cc(=O)[nH]c2c1-c1nc(no1)-c1ccc(C)cc1)C1CCNCC1
Show InChI InChI=1S/C21H22N6O2/c1-12-3-5-15(6-4-12)19-24-21(29-26-19)18-13(2)25-27-16(11-17(28)23-20(18)27)14-7-9-22-10-8-14/h3-6,11,14,22H,7-10H2,1-2H3,(H,23,28)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 11n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297791
PNG
(Ethyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo...)
Show SMILES CCOC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C14H18N4O3/c1-2-21-14(20)10-8-16-18-11(7-12(19)17-13(10)18)9-3-5-15-6-4-9/h7-9,15H,2-6H2,1H3,(H,17,19)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 11n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298161
PNG
(Cyclobutyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-d...)
Show SMILES Cc1nn2c(cc(=O)[nH]c2c1C(=O)OC1CCC1)C1CCNCC1
Show InChI InChI=1S/C17H22N4O3/c1-10-15(17(23)24-12-3-2-4-12)16-19-14(22)9-13(21(16)20-10)11-5-7-18-8-6-11/h9,11-12,18H,2-8H2,1H3,(H,19,22)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 11n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298098
PNG
(3-(4-ethyl-1,3-thiazol-2-yl)-7-(piperidin-4-yl)pyr...)
Show SMILES CCc1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C16H19N5OS/c1-2-11-9-23-16(19-11)12-8-18-21-13(7-14(22)20-15(12)21)10-3-5-17-6-4-10/h7-10,17H,2-6H2,1H3,(H,20,22)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 11n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297850
PNG
(3-(Phenylsulfonyl)-7-(piperidin-4-yl)pyrazolo[1,5-...)
Show SMILES O=c1cc(C2CCNCC2)n2ncc(c2[nH]1)S(=O)(=O)c1ccccc1
Show InChI InChI=1S/C17H18N4O3S/c22-16-10-14(12-6-8-18-9-7-12)21-17(20-16)15(11-19-21)25(23,24)13-4-2-1-3-5-13/h1-5,10-12,18H,6-9H2,(H,20,22)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 12n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298037
PNG
(3-{5-[4-methyl-2-(trifluoromethyl)phenyl]-1,2,4-ox...)
Show SMILES Cc1ccc(-c2nc(no2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(c1)C(F)(F)F
Show InChI InChI=1S/C21H19F3N6O2/c1-11-2-3-13(15(8-11)21(22,23)24)20-28-18(29-32-20)14-10-26-30-16(9-17(31)27-19(14)30)12-4-6-25-7-5-12/h2-3,8-10,12,25H,4-7H2,1H3,(H,27,31)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 12n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298114
PNG
(3-[(3,3-difluoroazetidin-1-yl)carbonyl]-7-(piperid...)
Show SMILES FC1(F)CN(C1)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C15H17F2N5O2/c16-15(17)7-21(8-15)14(24)10-6-19-22-11(5-12(23)20-13(10)22)9-1-3-18-4-2-9/h5-6,9,18H,1-4,7-8H2,(H,20,23)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 12n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298238
PNG
(3-[3-(2-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-meth...)
Show SMILES Cc1nn2c(cc(=O)[nH]c2c1-c1nc(no1)-c1ccccc1F)C1CCNCC1
Show InChI InChI=1S/C20H19FN6O2/c1-11-17(20-24-18(26-29-20)13-4-2-3-5-14(13)21)19-23-16(28)10-15(27(19)25-11)12-6-8-22-9-7-12/h2-5,10,12,22H,6-9H2,1H3,(H,23,28)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 12n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297809
PNG
(7-(Piperidin-4-yl)-3-(3-propyl-1,2,4-oxadiazol-5-y...)
Show SMILES CCCc1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C16H20N6O2/c1-2-3-13-19-16(24-21-13)11-9-18-22-12(8-14(23)20-15(11)22)10-4-6-17-7-5-10/h8-10,17H,2-7H2,1H3,(H,20,23)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 12n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297842
PNG
((−)-trans-7-(2-Methylpiperidin-4-yl)-5-oxo-4...)
Show SMILES CC1CC(CCN1)c1cc(=O)[nH]c2c(cnn12)C#N
Show InChI InChI=1S/C13H15N5O/c1-8-4-9(2-3-15-8)11-5-12(19)17-13-10(6-14)7-16-18(11)13/h5,7-9,15H,2-4H2,1H3,(H,17,19)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 12n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297797
PNG
(N-Benzyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyraz...)
Show SMILES O=C(NCc1ccccc1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C19H21N5O2/c25-17-10-16(14-6-8-20-9-7-14)24-18(23-17)15(12-22-24)19(26)21-11-13-4-2-1-3-5-13/h1-5,10,12,14,20H,6-9,11H2,(H,21,26)(H,23,25)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 13n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298061
PNG
(3-(5-methyl-4-phenyl-1,3-thiazol-2-yl)-7-(piperidi...)
Show SMILES Cc1sc(nc1-c1ccccc1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C21H21N5OS/c1-13-19(15-5-3-2-4-6-15)25-21(28-13)16-12-23-26-17(11-18(27)24-20(16)26)14-7-9-22-10-8-14/h2-6,11-12,14,22H,7-10H2,1H3,(H,24,27)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 13n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297808
PNG
(3-(3-Isopropyl-1,2,4-oxadiazol-5-yl)-7-(piperidin-...)
Show SMILES CC(C)c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C16H20N6O2/c1-9(2)14-20-16(24-21-14)11-8-18-22-12(7-13(23)19-15(11)22)10-3-5-17-6-4-10/h7-10,17H,3-6H2,1-2H3,(H,19,23)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 13n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297837
PNG
(3-(3-Methoxyphenyl)-7-(piperidin-4-yl)pyrazolo[1,5...)
Show SMILES COc1cccc(c1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C18H20N4O2/c1-24-14-4-2-3-13(9-14)15-11-20-22-16(10-17(23)21-18(15)22)12-5-7-19-8-6-12/h2-4,9-12,19H,5-8H2,1H3,(H,21,23)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 13n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297824
PNG
(4-[5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,...)
Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3ccc(cc3)C#N)c2[nH]1
Show InChI InChI=1S/C18H17N5O/c19-10-12-1-3-13(4-2-12)15-11-21-23-16(9-17(24)22-18(15)23)14-5-7-20-8-6-14/h1-4,9,11,14,20H,5-8H2,(H,22,24)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 13n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297815
PNG
((−)-trans-3-Chloro-7-(2-methylpiperidin-4-yl...)
Show SMILES CC1CC(CCN1)c1cc(=O)[nH]c2c(Cl)cnn12
Show InChI InChI=1S/C12H15ClN4O/c1-7-4-8(2-3-14-7)10-5-11(18)16-12-9(13)6-15-17(10)12/h5-8,14H,2-4H2,1H3,(H,16,18)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 14n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297847
PNG
(7-(Piperidin-4-yl)-3-[3-(trifluoromethoxy)phenyl]p...)
Show SMILES FC(F)(F)Oc1cccc(c1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C18H17F3N4O2/c19-18(20,21)27-13-3-1-2-12(8-13)14-10-23-25-15(9-16(26)24-17(14)25)11-4-6-22-7-5-11/h1-3,8-11,22H,4-7H2,(H,24,26)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 14n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297939
PNG
(7-(piperidin-4-yl)-3-{3-[2-(trifluoromethoxy)pheny...)
Show SMILES FC(F)(F)Oc1ccccc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C20H17F3N6O3/c21-20(22,23)31-15-4-2-1-3-12(15)17-27-19(32-28-17)13-10-25-29-14(9-16(30)26-18(13)29)11-5-7-24-8-6-11/h1-4,9-11,24H,5-8H2,(H,26,30)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 14n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298177
PNG
(3-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-7-(piperidi...)
Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3noc(n3)C3CC3)c2[nH]1
Show InChI InChI=1S/C16H18N6O2/c23-13-7-12(9-3-5-17-6-4-9)22-15(19-13)11(8-18-22)14-20-16(24-21-14)10-1-2-10/h7-10,17H,1-6H2,(H,19,23)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 14n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297798
PNG
(3-(Morpholin-4-ylcarbonyl)-7-(piperidin-4-yl)pyraz...)
Show SMILES O=C(N1CCOCC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C16H21N5O3/c22-14-9-13(11-1-3-17-4-2-11)21-15(19-14)12(10-18-21)16(23)20-5-7-24-8-6-20/h9-11,17H,1-8H2,(H,19,22)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 14n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298154
PNG
(Methyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazol...)
Show SMILES COC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C13H16N4O3/c1-20-13(19)9-7-15-17-10(6-11(18)16-12(9)17)8-2-4-14-5-3-8/h6-8,14H,2-5H2,1H3,(H,16,18)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 14n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298247
PNG
(3-[5-(3-fluoro-4-methoxybenzyl)-1,3,4-oxadiazol-2-...)
Show SMILES COc1ccc(Cc2nnc(o2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1F
Show InChI InChI=1S/C21H21FN6O3/c1-30-17-3-2-12(8-15(17)22)9-19-26-27-21(31-19)14-11-24-28-16(10-18(29)25-20(14)28)13-4-6-23-7-5-13/h2-3,8,10-11,13,23H,4-7,9H2,1H3,(H,25,29)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 14n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297796
PNG
(N-Isobutyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyr...)
Show SMILES CC(C)CNC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C16H23N5O2/c1-10(2)8-18-16(23)12-9-19-21-13(7-14(22)20-15(12)21)11-3-5-17-6-4-11/h7,9-11,17H,3-6,8H2,1-2H3,(H,18,23)(H,20,22)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 14n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297825
PNG
(3-(3-Chlorophenyl)-7-(piperidin-4-yl)pyrazolo[1,5-...)
Show SMILES Clc1cccc(c1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C17H17ClN4O/c18-13-3-1-2-12(8-13)14-10-20-22-15(9-16(23)21-17(14)22)11-4-6-19-7-5-11/h1-3,8-11,19H,4-7H2,(H,21,23)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 14n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298065
PNG
(3-[5-(2-chlorobenzyl)-1,3,4-oxadiazol-2-yl]-7-(pip...)
Show SMILES Clc1ccccc1Cc1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C20H19ClN6O2/c21-15-4-2-1-3-13(15)9-18-25-26-20(29-18)14-11-23-27-16(10-17(28)24-19(14)27)12-5-7-22-8-6-12/h1-4,10-12,22H,5-9H2,(H,24,28)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 14n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298182
PNG
(3-(5-Cyclopentyl-1,2,4-oxadiazol-3-yl)-7-(piperidi...)
Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3noc(n3)C3CCCC3)c2[nH]1
Show InChI InChI=1S/C18H22N6O2/c25-15-9-14(11-5-7-19-8-6-11)24-17(21-15)13(10-20-24)16-22-18(26-23-16)12-3-1-2-4-12/h9-12,19H,1-8H2,(H,21,25)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 14n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297810
PNG
(3-(3-Phenyl-1,2,4-oxadiazol-5-yl)-7-(piperidin-4-y...)
Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3nc(no3)-c3ccccc3)c2[nH]1
Show InChI InChI=1S/C19H18N6O2/c26-16-10-15(12-6-8-20-9-7-12)25-18(22-16)14(11-21-25)19-23-17(24-27-19)13-4-2-1-3-5-13/h1-5,10-12,20H,6-9H2,(H,22,26)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 15n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298005
PNG
(3-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]-7-(pip...)
Show SMILES Cc1ccc(cc1)-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C20H20N6O2/c1-12-2-4-14(5-3-12)20-24-18(25-28-20)15-11-22-26-16(10-17(27)23-19(15)26)13-6-8-21-9-7-13/h2-5,10-11,13,21H,6-9H2,1H3,(H,23,27)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 15n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM298180
PNG
(3-[5-(2-Methylprop-1-en-1-yl)-1,2,4-oxadiazol-3-yl...)
Show SMILES CC(C)=Cc1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C17H20N6O2/c1-10(2)7-15-21-16(22-25-15)12-9-19-23-13(8-14(24)20-17(12)23)11-3-5-18-6-4-11/h7-9,11,18H,3-6H2,1-2H3,(H,20,24)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 15n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297793
PNG
(Benzyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazol...)
Show SMILES O=C(OCc1ccccc1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C19H20N4O3/c24-17-10-16(14-6-8-20-9-7-14)23-18(22-17)15(11-21-23)19(25)26-12-13-4-2-1-3-5-13/h1-5,10-11,14,20H,6-9,12H2,(H,22,24)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 15n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297830
PNG
(3-(4-Methoxyphenyl)-7-(piperidin-4-yl)pyrazolo[1,5...)
Show SMILES COc1ccc(cc1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C18H20N4O2/c1-24-14-4-2-12(3-5-14)15-11-20-22-16(10-17(23)21-18(15)22)13-6-8-19-9-7-13/h2-5,10-11,13,19H,6-9H2,1H3,(H,21,23)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 15n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297794
PNG
(N-Ethyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazo...)
Show SMILES CCNC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1
Show InChI InChI=1S/C14H19N5O2/c1-2-16-14(21)10-8-17-19-11(7-12(20)18-13(10)19)9-3-5-15-6-4-9/h7-9,15H,2-6H2,1H3,(H,16,21)(H,18,20)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 15n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Tissue-type plasminogen activator


(Homo sapiens (human))
BDBM297836
PNG
(7-(Piperidin-4-yl)-3-(2-thienyl)pyrazolo[1,5-a]pyr...)
Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3cccs3)c2[nH]1
Show InChI InChI=1S/C15H16N4OS/c20-14-8-12(10-3-5-16-6-4-10)19-15(18-14)11(9-17-19)13-2-1-7-21-13/h1-2,7-10,16H,3-6H2,(H,18,20)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 15n/an/an/an/an/an/a



BAYER PHARMA AKTIENGESELLSCHAFT

US Patent


Assay Description
The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...


US Patent US10118930 (2018)

More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 465 total )  |  Next  |  Last  >>
* indicates data uncertainty>20%